Value Through Innovation19 December 2014
December 03, 2010

Boehringer Ingelheim Introduces Five New Vetera® Vaccines

Portfolio Features 7-way and 8-way protection with one convenient vaccine

Boehringer Ingelheim Vetmedica, Inc. (BIVI), announces the introduction of five new Vetera® vaccines, including Vetera Gold that offers 7-way protection, and Vetera Gold + VEE, the only equine vaccine with 8-way disease protection in one convenient vaccine. The addition of the five Vetera vaccines in various combinations allows veterinarians the ability to customize vaccination protocols to meet the unique needs of each horse.

Vetera vaccines incorporate the 2005 West Nile virus (WNV) horse isolate that protects against the strain most likely to infect horses today and includes duration of immunity against WNV for at least 12 months in horses as young as four months of age. In addition, the Vetera vaccines include the Ohio/2003, Kentucky/95, and NewMarket/2/93 influenza strains as recommended by the Expert Surveillance Panel on Equine Influenza.

The Vetera Gold portfolio of combination vaccines offers up to 8-way disease protection and various other vaccine combinations through the use of Ultrafil™ Purification Technology.

“The Ultrafil Purification Technology eliminates most of the extraneous proteins and cellular debris so the immune system of the horse can focus on relevant antigens. It’s also a key process when combining up to eight antigens in one vaccine that is administered in a 1 mL dose,” says Dr. John Tuttle, BIVI equine technical services veterinarian.

Proven using aggressive intrathecal and heterologous challenge studies, Vetera Gold + VEE was demonstrated to be 99 percent reaction-free in a multi-state study comprising 1,760 does.1

“While Vetera Gold + VEE offers up to 8-way disease protection with one vaccine, the needs of each horse are different depending on a risk-based analysis,” says Tuttle “Therefore, several additional combination vaccines in the Vetera portfolio have been developed to help meet those individual disease protection needs.”

In addition to Vetera Gold and Vetera Gold+VEE, the vaccine portfolio offers protection against EIV, EHV-1, EHV-4, VEE, EEE, WEE, tetanus and WNV in various combinations. The portfolio also includes:

Vetera® VEWT+WNV
Vetera® EWT+WNV
Vetera® WNV

For more information on Vetera Gold vaccines, contact Boehringer Ingelheim Vetmedica at 800-325-9167, or visit

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

For Boehringer Ingelheim—and its employees—carrying a good share of social responsibility is an important component in its business culture. Both global commitments in social projects and properly caring for all its employees are included. Respect, equal opportunity, and the balance of career and family life form the basis for mutual cooperation. And, environmental protection and sustainability are always the main focus during any of Boehringer Ingelheim’s undertakings.

In 2010, Boehringer Ingelheim posted net sales of approximately $16.7 billion (about 12.6 billion euro) while spending almost 24% of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information, please visit and follow us on Twitter at

Contact Information

  • Boehringer Ingelheim Vetmedica, Inc.

    3902 Gene Field Road
    St. Joseph, Missouri 64506